← Back to patent-cliff list
EXT-608
Tier C — Watch / tradeEXT-608
Extend Biosciences Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PTHR
Indications (approved)：甲状旁腺功能减退症
Regional status
US
Phase I
2022-06-23
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of EXT-608?
Approved indications include: 甲状旁腺功能减退症.
When does the EXT-608 patent expire?
No public expiry year is available for EXT-608 yet; this page updates once verified.
How do I get a quote for EXT-608 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30